This is a multicenter, randomized, double-blinded Phase 3 study to assess the efficacy and safety of two different doses of ianalumab (3 and 9 mg/kg) compared to placebo in adult participants with primary ITP.
This is a multicenter, randomized, double-blinded Phase 3 study to assess the efficacy and safety of two different doses of ianalumab (3 and 9 mg/kg) compared to placebo in adult participants with primary ITP.
